Themis Medicare Limited , a prominent player in the pharmaceutical sector, has reported a financial setback in its Q2 results for the fiscal year 2026. The company faced significant challenges that led to a substantial downturn in its financial performance compared to the same period last year.

Financial Highlights

All figures in Rs. lakhs

Key Developments

Merger Withdrawal

The company's Board withdrew the proposed merger scheme with Gujarat Themis Biosyn Limited, which was originally approved in November 2024. Gujarat Themis Biosyn decided to focus on its core fermentation-based pharmaceutical business and withdrew from the merger in June 2025.

UK Subsidiary

Themis Medicare received approval for striking off its UK subsidiary Carpo Medicals Limited, resulting in exceptional items of Rs 129.39 lakhs.

Business Focus

Themis Medicare will continue focusing on its domestic pharmaceutical formulations business. The company operates solely in the pharmaceuticals segment.

Future Outlook

While specific guidance for future quarters was not provided, the withdrawal of the planned merger with Gujarat Themis Biosyn Limited suggests a strategic refocus. The company's decision to concentrate on its core domestic formulations business indicates its commitment to achieving long-term sustainable growth.

Investors and stakeholders will be closely monitoring Themis Medicare's performance in the coming quarters for signs of recovery and the effectiveness of its renewed focus on core operations.

Themis Medicare Limited will need to address the challenges that led to this quarter's performance and implement strategies to return to profitability in the coming periods.

Themis Medicare Limited , a prominent player in the pharmaceutical industry, has announced several key decisions following its 55th Annual General Meeting (AGM) held on September 12. The company has declared a dividend, appointed a new independent director, and selected a new secretarial auditor, signaling important developments for shareholders and stakeholders alike.

Dividend Declaration

The company's board has approved a dividend of Rs 0.50 per equity share, representing a 50% return on the face value of Re 1 per share. This dividend declaration amounts to a total payout of Rs 4.60 crore. The move demonstrates Themis Medicare's commitment to delivering value to its shareholders despite the challenging business environment.

New Independent Director Appointment

In a significant board-level change, Ms. Neha Thakore has been appointed as an Independent Woman Director of Themis Medicare. Her appointment is effective from August 1, for a five-year term extending until July 31. Ms. Thakore brings over 25 years of pharmaceutical industry experience to the board, which is expected to contribute valuable insights to the company's strategic direction.

Ms. Thakore's extensive background includes her current roles as Managing Partner of Rifa Pharma and Chief Operating Officer & Director at Avik Pharmaceutical Ltd. Her expertise spans business development, operations management, and international regulatory affairs. Additionally, she holds leadership positions in various industry committees, serving as the Chairperson of IDMA POSH, HR & ESG Committees.

Secretarial Auditor Appointment

The company has also appointed M/s. SAV & Associates LLP as its Secretarial Auditor for a term of five consecutive financial years. CS Shirish Shetye will serve as the representative for this role. This appointment ensures compliance with regulatory requirements and maintains transparency in the company's secretarial practices.

AGM Proceedings and Other Resolutions

During the AGM, shareholders approved several other resolutions, including:

1. Adoption of the Audited Standalone and Consolidated Financial Statements.
2. Re-appointment of Dr. Adam Demeter as a director, who was retiring by rotation.
3. Ratification of the remuneration for the Cost Auditor.
4. Approval for the payment of commission to Non-Executive Directors.

The meeting, which commenced at 10:00 AM and concluded at 11:00 AM, was held at the company's registered office in Vapi, Gujarat. Dr. Dinesh S. Patel, Chairman of Themis Medicare, presided over the proceedings.

These decisions reflect Themis Medicare's focus on corporate governance, shareholder returns, and strategic growth. The appointment of Ms. Thakore as an Independent Director, in particular, is expected to bring fresh perspectives to the company's board, potentially influencing its future direction in the competitive pharmaceutical landscape.